VICURON HOLDINGS
PharmaVICURON HOLDINGS is a pharmaceutical company focused on Infectious Disease.
VICURON HOLDINGS's Key Drugs
VICURON HOLDINGS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
VICURON HOLDINGS's Recent FDA Approvals
New NDA/BLA approvals for VICURON HOLDINGS over the last two years — novel drugs only, excluding generics and label supplements.
VICURON HOLDINGS's Therapeutic Areas
VICURON HOLDINGS's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VICURON HOLDINGS's Top Competitors
VICURON HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VICURON HOLDINGS Pipeline Snapshot
Active clinical trials for VICURON HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2006-02-17
- Latest
- 2020-10-05
- Applications
- 1